Agios Pharmaceuticals, Inc. (AGIO)

33,66 +1,16 (+3,57%) Börsenschluss: 04:00PM EDT

Agios Pharmaceuticals, Inc.

88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 383

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Brian M. Goff M.B.A.	CEO & Director	1,23M	N/A	1969
Ms. Cecilia Jones	Chief Financial Officer	403,36k	N/A	1975
Mr. James William Burns	Corporate Secretary & Chief Legal Officer	660,33k	N/A	1978
Dr. Sarah Gheuens M.D., Ph.D.	Chief Medical Officer and Head of Research & Development	769,2k	N/A	1980
Dr. Lewis Clayton Cantley Ph.D.	Co-Founder & Member of Scientific Advisory Board	50k	N/A	1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1946
Dr. Craig B. Thompson M.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	1953
Dr. Shin-San Su Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1956
Dr. Clive Patience Ph.D.	Chief Technical Operations Officer	N/A	N/A	1964
Mr. Christopher J. M. Taylor	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Agios Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 5, Vorstand: 2, Shareholderrechte: 7, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.